Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Study to Assess [Lu-177]Lu-PSMA-R2 (AAA602) and [Ac-225]Ac-PSMA-R2 (AAA802) in Participants with PSMA-positive HRLPC (NeoPSMA)

Phase III Radium 223 mCRPC-PEACE III (PEACE III)

A Study to Assess How Radium-223 Distributes in the Body of Patients with Prostate Cancer Which Spread to the Bones

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu-177 Edotreotide Therapy in Pediatric Participants with SSTR-positive Tumors (KinLET)

Abemaciclib Before Lu-177-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT)

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Neuroendocrine Tumors

A Dose Finding Study of [Lu-177]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

An Open-label Study Comparing Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI versus AAA617 in PSMA Positive First-line mCRPC (PSMAndARPI)

Phase I Dose-escalation Study of Fractionated Lu-177-PSMA-617 for Progressive Metastatic CRPC